Role of genetic biomarkers in clinical assessment of prostate cancer

产品描述：该PPA的总体假设是确定某些遗传标记物的风险评估，如miRNA，单核苷酸错配修复基因或SNP，以及X连锁基因（如TSPX），因为有证据表明它们与前列腺癌相关。 第一个项目是研究可能作为前列腺癌标志物的miRNA，其作用是抑制致癌或抑癌基因的表达。这些研究旨在阐明控制这些过程的潜在机制。第二个项目是研究错配修复（MMR）基因中SNP在前列腺癌易感性和进展中的作用。第三个项目是研究X连锁肿瘤抑制基因（TSPX）与前列腺癌风险的关系，TSPX是一种肿瘤抑制因子和AR功能的辅助抑制因子，参与前列腺癌的风险和进展。 PPA中的三个项目将由三个核心支持：1）行政核心; 2）组织/形态学/分子核心; 3）统计核心。 重要性：优势：在大量前列腺标本（在不同的病理阶段）的前列腺癌的三种类型的分子生物标志物的表达的研究代表了一个重要的一步，朝着发展一个系统的患者识别其疾病进展的潜力。这些知识在设计治疗方法时可能很有价值。这项研究也将有助于目前缺乏的前列腺癌病理生物学方面的知识。对这三种生物标志物功能的分子机制的研究也得到了很好的考虑，并将推进有关这些生物标志物功能的基础知识。特别值得注意的一点是，沿着所提出的路线沿着的分子生物标志物的研究以前没有进行过，这使得这是一个非常新颖的努力。拟议研究的成功可以让莱亚

Description: The overall hypothesis of this PPA is to identify risk assessment of certain genetic markers such as miRNAs, single nucleotide mismatch repair genes or SNPs, and X-linked genes (such as TSPX) since there is evidence that they are associated with prostate cancer. The first project is to investigate the miRNAs that may serve as markers of prostate cancer by virtue of their action in suppression of oncogenic or tumor suppressor gene expression. The studies aim at delineating the underlying mechanisms that control these processes. The second project is to investigate the role of SNPs in mismatched repair (MMR) genes in prostate cancer susceptibility and progression. The third project is to investigate involvement in prostate cancer risk of the X-linked tumor suppressor gene (TSPX) which is a tumor repressor and corepressor for AR functions for its involvement in prostate cancer risk and progression. The three projects in the PPA will be supported by three Cores: 1) Administrative Core; 2) Tissue/Morphology/Molecular Core; and 3) Statistical Core. Significance: Strengths: The study of the expression of three types of molecular biomarkers of prostate cancer in a large number prostate specimens (at different stages of pathology) represents an important step towards developing a system of patient identification with respect to their potential for disease progression. This knowledge could be of much value in devising therapy approaches. This research will also contribute to the aspect of knowledge on prostate cancer pathobiology that is currently missing. Studies on the molecular mechanisms of the functions of the three types of biomarkers are also well considered and will advance the fundamental knowledge pertaining to the function of these biomarkers. A particularly noteworthy point is that investigation of molecular biomarkers along the proposed lines has not been undertaken previously making this a highly novel endeavor. The success in the proposed studies could lea